An audit of docetaxel for 2nd line treatment of patients with advanced non small cell lung cancer (NSCLC): toxicities and outcomes in NHS Tayside 2005-2010

S. Capaldi; H. Lord; E. M. Rankin; E. Brown

doi:10.1016/S0169-5002(12)70021-1

An audit of docetaxel for 2nd line treatment of patients with advanced non small cell lung cancer (NSCLC): toxicities and outcomes in NHS Tayside 2005-2010

S. Capaldi
, H. Lord
, E. M. Rankin
, E. Brown

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	S7
Number of pages	1
Journal	Lung Cancer
Volume	75
DOIs	https://doi.org/10.1016/S0169-5002(12)70021-1
Publication status	Published - 2012

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1016/S0169-5002(12)70021-1

Cite this

@article{b75e488e20494ccbb125a8ce14fc6b48,

title = "An audit of docetaxel for 2nd line treatment of patients with advanced non small cell lung cancer (NSCLC): toxicities and outcomes in NHS Tayside 2005-2010",

author = "S. Capaldi and H. Lord and Rankin, \{E. M.\} and E. Brown",

year = "2012",

doi = "10.1016/S0169-5002(12)70021-1",

language = "English",

volume = "75",

pages = "S7 ",

journal = "Lung Cancer",

issn = "0169-5002",

publisher = "Elsevier",

}

TY - JOUR

T1 - An audit of docetaxel for 2nd line treatment of patients with advanced non small cell lung cancer (NSCLC): toxicities and outcomes in NHS Tayside 2005-2010

AU - Capaldi, S.

AU - Lord, H.

AU - Rankin, E. M.

AU - Brown, E.

PY - 2012

Y1 - 2012

U2 - 10.1016/S0169-5002(12)70021-1

DO - 10.1016/S0169-5002(12)70021-1

M3 - Article

SN - 0169-5002

VL - 75

SP - S7

JO - Lung Cancer

JF - Lung Cancer

ER -